Rhubarb-Derived drug could tackle fatty liver
NCT ID NCT07199933
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether diacerein, a drug made from a compound found in rhubarb, can help people with metabolic fatty liver disease. About 74 adults will receive either diacerein or a placebo for 24 weeks. The main goal is to see if the drug reduces fat in the liver, measured by MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Diacerein (a derivative of rhein, the active compound in rhubarb)
- What this could lead to
- If successful, this could point toward a new treatment option for metabolic fatty liver disease, a condition with no approved drugs.
- What could go wrong
- This is a small, early-phase trial with only 74 participants. The drug may not reduce liver fat more than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAFLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a malaria drug melt liver fat? new trial investigates
- Reishi mushroom tested as fatty liver treatment in new study
- Gut health and gym: new combo tackles fatty liver
- Fatty liver mystery: 1,000 rural bangladeshis to be screened
- Could a daily pill slow kidney failure in fatty liver patients?
- Fatty liver drug hope: semaglutide shows promise in Long-Term study